Larimar Therapeutics, Inc. (LRMR) Misses Q3 EPS by 20c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q3 EPS of ($0.61), $0.20 worse than the analyst estimate of ($0.41).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Morgan Stanley Upgrades Galp Energia SGPS SA (GALP:LI) (GLPEF) to Overweight
• Berenberg Starts Brooks Macdonald Group PLC (BRK:LN) at Buy